Whitehawk Therapeutics and Tempus AI Collaborate to Support Oncology Pipeline Development.
ByAinvest
Thursday, Oct 16, 2025 11:54 am ET1min read
TEM--
The collaboration will utilize Tempus AI's de-identified multimodal database, which includes real-world patient data, according to a MarketScreener release. This data will help Whitehawk Therapeutics refine its clinical trial designs and identify patient populations with the greatest unmet medical needs. The partnership centers on Whitehawk's ADC portfolio, which includes three assets targeting clinically validated proteins PTK7, MUC16, and SEZ6, expressed in lung and gynecological cancers.
A key aspect of the collaboration involves establishing concordance between RNA expression testing and immunohistochemistry (IHC) testing. Whitehawk aims to validate RNA testing as a reliable alternative to IHC for patient identification, which could improve clinical trial recruitment and treatment efficacy.
Whitehawk's President and CEO, Dave Lennon, highlighted the importance of this work, noting that RNA testing offers advantages over traditional IHC methods in terms of objectivity, reproducibility, and scalability. Tempus AI's Chief Operating Officer, Ryan Fukushima, emphasized the potential of combining Tempus' multimodal data with Whitehawk's ADC expertise to validate the portfolio and inform indication prioritization for clinical development programs.
The partnership provides Whitehawk with access to real-world evidence as it advances its cancer drug programs. Tempus AI's AI platform and comprehensive patient database will be instrumental in this endeavor.
WHWK--
Whitehawk Therapeutics (WHWK) stock is up 32.48% after announcing a multi-year collaboration with Tempus AI to support the development of its oncology pipeline, according to Parameter.
Whitehawk Therapeutics (WHWK) stock surged 32.48% on Wednesday following the announcement of a multi-year collaboration with Tempus AI. The partnership aims to leverage Tempus AI's real-world dataset to support the development of Whitehawk's oncology pipeline, focusing on refining clinical trial designs and identifying patient populations with the highest levels of unmet need for Whitehawk's antibody drug conjugate (ADC) portfolio.The collaboration will utilize Tempus AI's de-identified multimodal database, which includes real-world patient data, according to a MarketScreener release. This data will help Whitehawk Therapeutics refine its clinical trial designs and identify patient populations with the greatest unmet medical needs. The partnership centers on Whitehawk's ADC portfolio, which includes three assets targeting clinically validated proteins PTK7, MUC16, and SEZ6, expressed in lung and gynecological cancers.
A key aspect of the collaboration involves establishing concordance between RNA expression testing and immunohistochemistry (IHC) testing. Whitehawk aims to validate RNA testing as a reliable alternative to IHC for patient identification, which could improve clinical trial recruitment and treatment efficacy.
Whitehawk's President and CEO, Dave Lennon, highlighted the importance of this work, noting that RNA testing offers advantages over traditional IHC methods in terms of objectivity, reproducibility, and scalability. Tempus AI's Chief Operating Officer, Ryan Fukushima, emphasized the potential of combining Tempus' multimodal data with Whitehawk's ADC expertise to validate the portfolio and inform indication prioritization for clinical development programs.
The partnership provides Whitehawk with access to real-world evidence as it advances its cancer drug programs. Tempus AI's AI platform and comprehensive patient database will be instrumental in this endeavor.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet